We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

67 hedge funds and large institutions have $12.1M invested in Tvardi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 8

2.11% more ownership

Funds ownership: 28% → 30.11% (+2.1%)

8% less funds holding

Funds holding: 73 → 67 (-6)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

88% less capital invested

Capital invested by funds: $102M → $12.1M (-$90.1M)

Holders
67
Holders Change
-6
Holders Change %
-8.22%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
30
Reduced
8
Closed
17
Calls
$95K
Puts
–
Net Calls
+$95K
Net Calls Change
-$1.55M

Top Buyers

Rank Fund Capital Flow
1
AFG
American Financial Group
Ohio
+$2M
2
Morgan Stanley
Morgan Stanley
New York
+$723K
3
SAM
Silvercrest Asset Management
New York
+$705K
4
Renaissance Technologies
Renaissance Technologies
New York
+$666K
5
BlackRock
BlackRock
New York
+$547K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$6.77M
2
VPC
Vestal Point Capital
New York
-$6.51M
3
Invesco
Invesco
Georgia
-$3.22M
4
PHP
Parkman Healthcare Partners
Connecticut
-$2.53M
5
BFM
Boothbay Fund Management
New York
-$787K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$123 – – –
LI
52
LRI Investments
Florida
$116 -$493 -55 -67%
ME
53
McIlrath & Eck
Washington
$86 – – –
HI
54
Harbour Investments
Wisconsin
$65 – – –
LSA
55
Leonteq Securities AG
Switzerland
$52 – – –
MCM
56
MAI Capital Management
Ohio
$43 – – –
IA
57
IFP Advisors
Florida
$26 +$54 +6 New
IAIM
58
International Assets Investment Management
Florida
$26 +$54 +6 New
EWA
59
EverSource Wealth Advisors
Alabama
$22 +$45 +5 New
SS
60
SBI Securities
Japan
$17 – – –
TC
61
Truvestments Capital
Florida
$17 – – –
FFA
62
Farther Finance Advisors
California
$13 – – –
SIS
63
Sound Income Strategies
Florida
$9 – – –
LFG
64
Larson Financial Group
Missouri
$9 +$18 +2 New
CPG
65
Cornerstone Planning Group
New Jersey
$4 -$305 -34 -97%
Comerica Bank
66
Comerica Bank
Texas
$4 – – –
FRA
67
Front Row Advisors
California
$4 – – –
6CM
68
683 Capital Management
New York
– -$6.77M -176,030 Closed
VPC
69
Vestal Point Capital
New York
– -$6.51M -167,000 Closed
Invesco
70
Invesco
Georgia
– -$3.22M -82,614 Closed
PHP
71
Parkman Healthcare Partners
Connecticut
– -$2.53M -65,000 Closed
BFM
72
Boothbay Fund Management
New York
– -$787K -20,189 Closed
SSA
73
Schonfeld Strategic Advisors
New York
– -$746K -19,132 Closed
MAM
74
Monaco Asset Management
Monaco
– -$530K -13,590 Closed
N
75
Nuveen
North Carolina
– -$232K -5,951 Closed
1 2
3
4

TVRD Hedge Fund Activity: Q4 2025 in Review

67 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2025, worth a combined $12.1M — down 88% from $102M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TVRD and 11 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 30 added.

The largest buyer was American Financial Group, opening a new position worth an estimated $2M. The largest seller was 683 Capital Management, exiting entirely with an estimated $6.77M sold.

  • 67 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2025, down from 73 in Q3 2025.
  • Funds reported $12.1M of Tvardi Therapeutics stock for Q4 2025, down 88% quarter-over-quarter.
  • 11 funds opened new Tvardi Therapeutics positions in Q4 2025 and 17 closed out, a net change of -6 holders.
  • The largest Tvardi Therapeutics buyer in Q4 2025 was American Financial Group, an estimated $2M added.
  • The largest Tvardi Therapeutics seller in Q4 2025 was 683 Capital Management, an estimated $6.77M sold.

Based on aggregated 13F filings for Q4 2025.